Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...

A new publication from Opto-Electronic Advances; DOI 10.29026/oea.2026.250149, discusses a quarter-wave geometric-phase route ...

From vision defects to rainbows and sky colour, here’s a quick-scoring, concept-based summary aligned with the CBSE dual exam ...

Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

With limited headcount and tight budgets, SME marketers discuss making more deliberate decisions about team structure, skills ...

Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, today announced interim data from a phase 1b study of ABX1100 ...

At Fruit Logistica, the VOG Consortium unveiled a new strategic concept inspired by the findings of an in-depth European ...

Summary Atmanirbharta in Defence has expanded production numbers, diversified the supplier base, and altered the political ...

Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa Guillain-Barré Syndrome (GBS) is the most frequent cause of acute ...

Hyundai’s performance division is preparing a fresh wave of serious hardware, and the message from the top is clear: the N ...

Journalist and author John Cassidy offers a historical compass to contemporary debates.